Spenser Lin No Comments

Healthcare News, Deals, and Investments Update October 5th, 2026

LECO_Weekly-Healthcare-News_10-05-2026Download

Healthcare Weekly News and Deals – Oct 5th, 2026

  1. Smart ring maker Oura has postponed its Nasdaq IPO, which would have raised up to $2.2 billion through the sale of 50 million shares, citing uncertainty in the listing market just eight days after formally launching the process. Oura delayed its planned Nasdaq listing despite what it described as strong demand and a strengthening of the business since the IPO process began. The company launched its plans on September 21 and had intended to raise up to $2.2 billion by selling 50 million shares. CEO Tom Hale said Oura aims to deliver an extraordinary IPO for employees and investors and has “the luxury of choosing our moment.” Oura says it is profitable, with revenue expected to grow 90% year over year in fiscal 2026. It follows Holtec Nuclear’s withdrawal earlier in the month. (Link)
  2. U.S. healthcare technology investor Thoreau has committed $500 million to launch Ortet, a frontier AI lab for health building models that connect patient biology, treatment and healthcare administration. Ortet launched on September 29, 2026 with a $500 million commitment from Thoreau, bringing together former drug industry and technology company researchers. The company plans to use the backing to build computing and data infrastructure, train and deploy health-focused models, and recruit researchers and engineers. Ortet has already secured an initial cluster of graphics processing units, the specialized chips used to train and run AI systems. Rather than targeting a single clinical task, the lab is building models intended to link patient biology, treatment and healthcare administration, making it one of the largest single capital commitments to a healthcare AI company at formation. (Link)
  3. Grindr (NYSE:GRND) has agreed to acquire PurposeMed, the parent company of HIV-prevention telehealth provider Freddie, in a $250 million cash-and-stock deal with up to $70 million of additional performance consideration. Grindr will pay $190 million in cash and $60 million in common stock for PurposeMed, with up to $70 million in further cash tied to Freddie’s 2027 performance and payable in 2028. The transaction is expected to close in the fourth quarter and is Grindr’s first major acquisition since its 2009 founding. CEO George Arison said the healthcare line could become as profitable and as large as the core business, and that building it internally would have taken two to three years. Grindr expects the combined U.S. telehealth and pharmacy business to generate more than $400 in monthly revenue per active patient, implying roughly $240 million of annual revenue at 50,000 patients. (Link)
  4. Inogen (NASD: INGN) has agreed to divest its U.S. oxygen rental business to national home respiratory provider Rotech Healthcare for estimated cash consideration of up to $25 million. Inogen (INGN) signed a definitive agreement to sell specified U.S. oxygen rental assets to Rotech Healthcare for total estimated cash consideration of up to $25 million, with closing expected in the fourth quarter of 2026. The rental business generated $24.3 million of revenue in the first half of 2026, a 9.8% year-over-year decline, and will be presented as discontinued operations beginning in Q3. Inogen expects the transactions to increase both its revenue growth rate and adjusted operating income. Subject to closing, the board approved a $15 million increase to the share repurchase authorization, taking it to $45 million through June 2028. (Link)
  5. Interpace Biosciences (IDXG) has filed terms for a $20 million offering of 3.1 million shares at an assumed $6.47 per share to support a proposed uplisting from OTC to Nasdaq. Interpace Biosciences (IDXG), the Parsippany, New Jersey molecular diagnostics company behind the ThyGeNEXT and ThyraMIR v2 thyroid tests, filed terms on September 25, 2026 for a $20 million deal covering 3.1 million shares at an assumed $6.47; the offering remains unpriced. The raise follows an August reverse stock split announced to support the proposed Nasdaq uplisting. Thyroid test volume rose from 25,200 in 2022 to 36,200 in 2025 and pro forma revenue grew from $20.3 million to $34.8 million, a 19.7% CAGR, after the company stopped accepting PancraGEN specimens in May 2025 following a loss of CMS reimbursement. (Link)
  6. KALA Bio (NASD: KALA) has signed a non-binding letter of intent to acquire 100% of a privately held U.S. telehealth management services organization for approximately $15 million in cash and KALA stock. KALA Bio (KALA) signed the LOI on September 24, 2026 for an MSO supporting a LegitScript-certified, NABP-accredited provider-led telehealth platform operating in all 50 states across GLP-1 weight management, hormone health, longevity and sexual wellness. The target generated roughly $12.7 million of unaudited revenue for the trailing twelve months ended August 2026, over $48 million of sales since its 2023 founding, has served more than 90,000 clients and is described as cash-flow positive. The cash portion would come from existing balance sheet resources, with closing targeted for late 2026 or early 2027. (Link)
  7. SpyGlass Pharma (NASD: SGP) has acquired Advanced Vision Science from Santen for about $13 million in cash. Advanced Vision Science has made intraocular lenses since 1975 and supplies Santen’s Eternity lens in Japan. It also licenses glistening-free hydrophobic acrylic material to Bausch + Lomb for the enVista line. Those supply and license arrangements stay in place. SpyGlass, which is developing a drug-pad lens implanted during cataract surgery for glaucoma, is buying the plant to secure commercial lens supply. (Link)
  8. Shionogi has agreed to acquire Austin-based IntraBio for $2.0 billion, adding the rare-disease therapy AQNEURSA. Shionogi is buying all outstanding shares of IntraBio, an Austin company founded in 2015, for $2.0 billion in upfront cash. IntraBio sells AQNEURSA, approved in the United States and Europe for neurological symptoms of Niemann-Pick disease type C and, as of September 18, for ataxia in ataxia-telangiectasia in the United States. The company becomes a subsidiary of Shionogi’s New Jersey unit. Closing is scheduled for November or December, subject to antitrust review. Shionogi bought the RADICAVA ALS franchise in April. (Link)
  9. AstraZeneca has agreed to invest $2 billion in newly issued equity of Summit Therapeutics (NASD: SMMT), taking about a 12 percent stake. AstraZeneca is buying convertible preferred equal to about 12 percent of Summit’s common stock, or 10.6 percent fully diluted. The stake sits alongside a clinical collaboration testing AstraZeneca’s Claudin-18.2 antibody-drug conjugate, sonesitatug vedotin, with Summit’s PD-1/VEGF bispecific ivonescimab in gastrointestinal cancers. Each company keeps rights to its own drug. The investment was announced September 29 and was expected to close within about a week. (Link)
  10. GE HealthCare (NASD: GEHC) has agreed to acquire SOFIE Biosciences from Trilantic North America for $945 million in cash. SOFIE is a U.S. contract manufacturer for PET radiopharmaceuticals, with 15 sites, 21 cyclotrons and a theranostics development site, plus U.S. rights to FAPI-74, a Phase III PET tracer aimed at pan-cancer imaging. The business will sit in GE HealthCare’s pharmaceutical diagnostics segment and gives the buyer a last-mile network for short-lived tracers. Closing is aimed at the first half of 2027, subject to regulatory approval. (Link)
  11. Lantern Pharma (NASD: LTRN) has agreed to sell 3,669,725 shares at $1.09 in a registered direct offering raising approximately $4 million, with up to $4 million more available from concurrent private placement warrants. Lantern Pharma (LTRN), a clinical-stage AI-native precision oncology company, entered a definitive agreement for a registered direct offering of 3,669,725 shares, or pre-funded warrants in lieu, priced at $1.09 each. Aggregate gross proceeds are expected to be about $4 million. In a concurrent private placement, investors receive unregistered warrants over an equal number of shares at a $1.09 exercise price, exercisable only after stockholder approval and expiring five years later; full cash exercise would add roughly $4 million. Closing was expected on or about September 30, 2026, with proceeds earmarked for working capital and general corporate purposes. (Link)
  12. Leica Biosystems, a Danaher (NYSE: DHR) company, has completed its acquisition of pre-analytical consumables maker StatLab Medical Products from private equity owners Linden Capital Partners and Audax Private Equity. Danaher (DHR) subsidiary Leica Biosystems completed its purchase of privately held StatLab Medical Products on September 28, 2026, acquiring the business from Linden Capital Partners and Audax Private Equity. Terms were not disclosed. The deal extends Leica’s end-to-end anatomic pathology portfolio across specimen collection and preparation, advanced staining, digital imaging and AI-enabled diagnosis. Management positioned the combination as a response to laboratories facing rising case volumes, increasing complexity and staffing pressure, and as support for Leica’s biopharma partnerships within Danaher’s connected diagnostics ecosystem. (Link)
  13. Goldman Sachs (NYSE: GS) and Charlesbank Capital Partners-backed MyEyeDr. has agreed to acquire the 300-plus office optometry division of Partners Group (SWX: PGHN)-owned EyeCare Partners for an undisclosed sum. MyEyeDr., backed by Goldman Sachs (GS) and Charlesbank Capital Partners, is buying EyeCare Partners’ optometry division, which spans more than 300 offices under the Clarkson Eyecare, EyeCare Associates, EyeCare Center, Nationwide Vision and The Eye Doctors brands. Partners Group (PGHN) acquired EyeCare Partners in a $2.2 billion deal in late 2019, while Goldman Sachs bought MyEyeDr. for $2.7 billion the same year; MyEyeDr. already runs roughly 1,000 locations across about 30 states. EyeCare Partners will apply proceeds to reduce debt and strengthen liquidity while focusing on ophthalmology and ambulatory surgical centers. Closing is expected in Q4 2026. (Link 1) (Link 2)
  14. APM Group has agreed to acquire occupational health provider Medcor, combining it with previously acquired WorkCare and its Assure employee assistance business into a 2,000-employee North American platform. APM Group announced on September 28 that it entered an agreement to acquire Medcor, subject to Federal Trade Commission approval, with financial terms and completion date undisclosed. The deal follows APM’s April acquisition of WorkCare. Combined with Assure, the three businesses would employ more than 2,000 people across 450 sites, with services in every U.S. state and territory and every Canadian province. The combined portfolio spans injury prevention, onsite medical services, occupational health screenings, injury triage, telehealth, case management, return-to-work support and mental health services. Medcor, founded in 1984, adds mobile occupational health and 24/7 telehealth. (Link)
  15. Flexpoint Ford has sold behavioral health pharmacy platform ArtesRx — a business it co-founded in 2023 with Dom Meffe — to healthcare specialist Linden Capital Partners. Flexpoint Ford announced the sale of ArtesRx to Linden Capital Partners for undisclosed terms, a sponsor-to-sponsor exit of a platform Flexpoint built from scratch just three years ago. ArtesRx, established in 2023 by Flexpoint and Dom Meffe, is a behavioral health pharmacy platform serving individuals who depend on complex medication regimens. Chicago-based Flexpoint, founded in 2005, writes $50 million to $500 million per transaction across minority and majority structures in both private and public companies. Linden, also Chicago-based and founded in 2004, invests exclusively in healthcare across services, products and distribution and prefers larger cheques. (Link)
  16. Charlesbank Capital Partners and Warburg Pincus-backed MB2 Dental has partnered with Honolulu-based Hawaii Pacific Dental Group in its 14th acquisition of 2026. MB2 Dental, the Dallas dental support organization backed by middle-market private equity firm Charlesbank Capital Partners and growth equity investor Warburg Pincus, formed a strategic partnership with Hawaii Pacific Dental Group. The Honolulu practice, led by Dr. Rohinton J. Patel, provides cosmetic, restorative, preventative and family dentistry. MB2 supports a nationwide network of more than 1,900 affiliated physicians and practice partners across general dentistry, orthodontics, cosmetic care and oral surgery. The transaction expands MB2’s footprint across Hawaii and the broader Pacific region and marks its 14th acquisition of 2026. Financial terms of the private transaction were not disclosed. Link (Link)
  17. Standard Dental Labs (OTCQB: TUTH) has acquired substantially all operating assets of Dr. Tooth, LLC — also known as Sheen Dental Laboratory and Hansen Incarnati — in a cash-and-stock asset purchase with earnout conditions. Standard Dental Labs (TUTH) closed the acquisition effective October 2, 2026, structured as an asset purchase combining cash and SDL common stock with performance conditions tied to retained customer revenue. Management estimates the acquired business adds just over $800,000 in annualized revenue, taking SDL’s estimated annualized base above $1.6 million and nearly doubling the prior estimate. SDL plans to move production to its Sarasota facility, reshoring work currently outsourced to China to lift utilization and facility profitability. Management believes the business can be rebuilt to more than $1.1 million in annualized revenue. (Link)
  18. Banner Capital, with healthcare private equity firm Seventeen Capital as strategic co-investor, has agreed to acquire Seaway Plastics Engineering, MME Group and Wright Engineered Plastics, forming medical device manufacturing platform Seaway Group under Executive Chairman Ron Labrum. Salt Lake City-based Banner Capital formed Seaway Group and entered a definitive agreement to acquire the three medical device contract manufacturers, with closing expected in the fourth quarter of 2026. Seventeen Capital, a healthcare private equity firm led by medical device executive Ron Labrum, is a strategic co-investor, and Labrum becomes Executive Chairman at close. Seaway Group is the third platform in Banner Capital Fund II, after Western Pavement Services and Roof Restoration Group. Banner targets founder-led Western U.S. businesses with $4 million to $15 million of EBITDA and managed $611 million as of June 30, 2026. (Link)
  19. Wandercraft has acquired Ekso Bionics from a subsidiary of ChronoScale Holdings (NASD: CHRN), uniting two medical exoskeleton pioneers into a global robotic mobility platform. Wandercraft acquired Ekso Bionics from a ChronoScale Holdings (CHRN) subsidiary in a transaction unanimously approved by both boards and signed and closed simultaneously; financial terms were not disclosed. The combination pairs Wandercraft’s advanced robotics, physical AI and EMEA leadership with Ekso’s U.S. presence, clinical evidence base and commercial reach. Atalante X and EksoNR support patients at more than 700 rehabilitation centers worldwide, with FDA clearances and CE marking covering stroke, spinal cord injury, multiple sclerosis and acquired brain injury, while Eve and Indego Personal address at-home mobility. Wandercraft will continue supporting all four products. (Link)
  20. The University of Kansas Health System has agreed to take full ownership of the St. Francis campus in Topeka from Ardent Health (NYSE: ARDT). The two have run St. Francis and affiliated Topeka sites as a joint venture since 2017, after the campus had been facing closure. Ardent has handled day-to-day operations. KU Health System has provided clinical and financial support. Ardent will stay involved for a period after closing. The transfer is expected by the end of 2026, subject to approvals. (Link)
  21. Biospring Partners has led a growth investment in CDMO Serán Bioscience alongside existing investors Vivo Capital and Bain Capital Life Sciences to fund a new commercial spray-drying facility in Bend, Oregon. Biospring Partners led the growth investment with continued participation from Vivo Capital, Bain Capital Life Sciences and Serán’s executive leadership. Proceeds support a greenfield commercial manufacturing facility on track for completion in Q3 2027, creating an integrated 200,000-plus square foot campus with OEB4 manufacturing, spray drying, nano-milling and finished-dose capabilities. Biospring, founded in 2020, is a healthcare growth buyout firm with more than $500 million under management focused on pharma services; Vivo manages roughly $5.8 billion. Serán employs over 200 people and plans up to 150 additional hires. (Link)
  22. Renovus Capital Partners portfolio company TJP has acquired life sciences market research firm Evolution Consulting & Research, completing an end-to-end research, strategy, creative, pull-through and analytics platform for pharma clients. TJP, a Conshohocken, Pennsylvania value and patient access agency owned by Renovus Capital Partners, acquired Evolution Consulting & Research. The add-on follows TJP’s earlier purchase of FX2 Virtual and gives clients continuity from upfront market research through strategy, creative, virtual field execution and analytics. CEO Rino Mariconda, also an operating partner at Renovus, said the deal fulfills the firm’s vision of a unified platform. Renovus, founded in 2010, invests in knowledge and talent industries including healthcare and life sciences services, and builds platforms through operational improvement and add-on acquisitions. Terms were undisclosed. (Link)
  23. Resonant Clinical Solutions has acquired Hamburg-based labfish rental solutions GmbH and its U.S. and U.K. affiliates, expanding its Equipment & Ancillaries business across Europe. Resonant Clinical Solutions, a Leesburg, Virginia clinical supply chain and sample lifecycle partner, acquired Labfish together with its U.S. and U.K. affiliates for undisclosed terms. Labfish rents scales, freezers, refrigerators, infusion pumps and monitors, supplies kitting and ancillaries, and operates one of the largest in-house calibration facilities serving clinical trials in Europe. It also provides Importer and Exporter of Record services and direct-to-patient logistics, working with partner depots in Argentina, Israel, Turkey and China to supply sites in more than 70 countries. Resonant has over 850 employees and has supported more than 2,500 clinical trials. (Link)
  24. Sheridan Capital Partners has acquired Durham, North Carolina-based single-use bioprocessing components supplier Carolina Components Group, its fourth platform acquisition of 2026. Chicago healthcare private equity firm Sheridan Capital Partners acquired Carolina Components Group, a 2020-founded supplier of ultra-pure components, custom-engineered single-use assemblies and process solutions serving more than 250 biopharmaceutical and contract manufacturing customers. CCG operates over 100,000 square feet of ISO Class 7 and Class 8 cleanroom and manufacturing space, scale Sheridan says regional competitors lack. Sheridan cited CCG’s supplier-agnostic model and its status as a founder-owned business at a growth inflection point. The deal is Sheridan’s fourth of 2026 after ICANotes, Tres Health and PtEverywhere. (Link)
  25. Chicago Pacific Founders has exited veterinary AI company CoVetAI following its acquisition by IDEXX Laboratories (NASD: IDXX), the first realization from CPF’s Pet Fund – Off Leash Capital. IDEXX Laboratories (IDXX) acquired CoVetAI, developer of an AI-powered clinical scribe and workflow platform for veterinary medicine, handing Chicago Pacific Founders the first realization from its specialist animal health fund. Financial terms were not disclosed. CPF was CoVet’s sole institutional investor and backed the company from an early stage; Pet Fund partner Gina Del Vecchio described IDEXX as the ideal owner to scale the product globally. The fund closed on September 16, 2026, holds six portfolio investments, and targets a companion animal market currently worth $288.4 billion and projected to reach $560.7 billion by 2034. (Link)
  26. Brady (NYSE: BRC) has sold its French first-aid business Securimed to Safe Life for about $59 million. Securimed, based in Cappelle-la-Grande, sells customized first-aid kits, protective equipment and emergency-response products, mostly to corporate health and safety departments in France. Brady bought the business in 2010. The price is about €53 million. Brady is an identification and safety-products company based in Milwaukee and is treating the unit as outside that core. (Link)

Venture Deals and Other

  1. Anthropic, PBC has confidentially submitted a draft registration statement on Form S-1 to the U.S. Securities and Exchange Commission for a proposed initial public offering of its common stock, with share count and price not yet set. Anthropic, PBC confidentially submitted a draft Form S-1 to the SEC for a proposed initial public offering of its common stock. The submission gives the AI developer the option to go public once the SEC completes its review, with any offering dependent on market conditions and other factors. The number of shares to be offered and the price have not yet been set. The announcement was published under Rule 135 of the Securities Act of 1933 and is not an offer to sell or a solicitation of an offer to buy securities. No valuation, timetable, exchange or selling shareholders were disclosed. (Link 1) (Link 2)
  2. Lux Capital and Natural Capital have co-led a $251 million Series D in El Segundo-based in-orbit pharmaceutical processing company Varda Space Industries, joined by Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital, at a $1.6 billion valuation. Lux Capital and Natural Capital led Varda Space Industries’ $251 million Series D, with Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital participating. The round values the microgravity-enabled life sciences company at $1.6 billion and lifts total capital raised to $598 million. Varda has completed six reentry missions since 2023, with more than a dozen launches and reentries planned through 2028. Proceeds will increase flight cadence and deepen pharmaceutical partnerships toward the first medicine manufactured in space. (Link)
  3. B Capital has led a $33 million Series B in Austin-based microbiome testing company Tiny Health, joined by Spero Ventures, The Venture City, Overwater Ventures, Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital led Tiny Health’s oversubscribed $33 million Series B, bringing total funding to $46 million. Existing backers Spero Ventures, The Venture City and Overwater Ventures participated alongside new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels and Pari Passu Ventures. B Capital manages more than $12 billion and takes a board seat through Senior Principal Nick Whitehead. Proceeds fund clinical research, practitioner education, the Powered by Tiny B2B platform and TinyAI, trained on nearly 200,000 microbiome profiles. Tiny Health also committed $5 million to a Microbiome Research Program. (Link)
  4. Canvas Ventures has led an oversubscribed $10 million Series A in San Francisco-based healthcare AI company Parakeet Health, with Blank Space Ventures, StoryHouse Ventures and HMC INQ participating. Canvas Ventures led Parakeet Health’s oversubscribed $10 million Series A, taking total funding to $13 million. The raise follows 10x annual recurring revenue growth over the past year. Parakeet’s platform manages inbound calls, proactive outreach, fax processing and web scheduling, and now serves six of the ten largest U.S. dermatology groups, supporting more than 2,800 providers across 1,100-plus locations. Canvas co-founder Rebecca Lynn cited the team’s ability to win major healthcare customers and deliver measurable ROI. Parakeet charges on a performance basis tied to verified results. Link (Link)
  5. Biotia has raised an oversubscribed $9 million financing from Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, alongside VillageMD co-founders Tim Barry and Clive Fields. New York clinical metagenomics company Biotia closed an oversubscribed $9 million round that exceeds its previously announced Series A. Investors include Convergent Ventures, DigitalDx Ventures, Cloquet Capital Partners, Continuum Health Ventures, I-Lab Angels, EGB Capital, Leawood Venture Capital, Red Bear Angels and Red Bear Ventures, plus VillageMD co-founders Tim Barry and Clive Fields. DigitalDx Ventures CEO Michele Colucci becomes board chair and Barry joins the board. Capital will scale Biotia’s New York laboratory, launch further women’s health diagnostics and expand into orthopedics. Its BIOTIA-ID urine test reports 97% sensitivity and 99% specificity. (Link)
  6. Cobalt Capital has led an undisclosed Series A in Los Angeles-based predictive movement health company p°Motion, joined by WME Group, Nimble Ventures, Canaan Ventures and Soul Ventures. Cobalt Capital led the Series A financing, building on support from a broader investor group including WME Group, Nimble Ventures, Canaan Ventures, Soul Ventures and strategic investors connected to professional sports, technology and institutional capital. Neither round size nor valuation was disclosed. Founded in 2019, p°Motion applies machine learning to an assessment methodology built on more than 40 years of movement research, and says it can identify certain injury risks up to 18 months before they occur — a company-reported claim without published validation data. Proceeds fund AI and engineering hiring plus commercial expansion into healthcare. (Link)
  7. Advent has led, and Temasek co-led, a $555 million Series G in Medicare Advantage insurer Devoted Health as part of a $1.18 billion financing. Devoted Health closed $555 million of Series G primary funding within a $1.18 billion primary and secondary financing. Advent led with Temasek as co-lead, joined by The Space Between — both independently and alongside Centricus — plus GIC, Franklin Templeton, Generation, VZVC, Emerson Collective, Premji Invest and Andreessen Horowitz. The same investors committed $622 million for a shareholder tender offer expected to close later in the fourth quarter. Membership has grown from 212,000 in December 2025 to 538,000 by September 2026, and Devoted is entering 342 new counties and five new states. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update September 8th, 2026

LECO_Weekly-Healthcare-News_9-8-2026Download

Healthcare Weekly News and Deals

  1. Oura Inc. has publicly filed its Form S-1 with the SEC for a Nasdaq listing under the ticker OURA, with existing investors reportedly seeking up to $3 billion at a valuation above $16 billion. The public file on 3 September replaces a 21 May confidential submission and attaches audited figures. Revenue reached $1.21 billion for the nine months to 30 June 2026, up 74% from $697.6 million; fiscal 2025 revenue was $907.9 million, up 123%. Gross margin improved to 55% from 51%. The $924.3 million net loss attributable to common stockholders is a $985.0 million deemed dividend on redeemable convertible preferred — a pre-IPO capital-structure entry, not operating deterioration. Last private mark was about $11 billion in October 2025. Hardware is still roughly 80% of revenue. (Link)
  2. Yellow Wood Partners to Buy Nestlé’s Mainstream Vitamins and Supplements Platform for $1 Billion Nestlé is keeping the premium practitioner-channel brands — Solgar and Pure Encapsulations — and selling the mass-market Holistic Health VMS book. That is how large strategics are now splitting consumer health: retain clinician-recommended margin, exit volume. Yellow Wood has run this carve-out playbook before. GLP-1-driven changes in nutrition behavior are reshuffling category economics; add-on activity is expected. (Link)
  3. Medtronic plc has committed about $700 million to Cornerstone Robotics and taken distribution rights to Cornerstone’s Sentire surgical system in selected markets outside the United States. Sentire will sit beside Hugo (Medtronic’s robotic-assisted surgery (RAS) system) rather than replace it. The system was built in-house, finished multi-specialty trials and received CE Mark in May 2026 for general, gynecologic, thoracic and urologic minimally invasive surgery, on top of China and Singapore approvals. Cornerstone runs three global R&D hubs, six business centers and a 30,000-square-meter plant in China; the console is dual-capable. Hugo is already in more than 35 countries, with procedures expected to exceed 50,000 this fiscal year. Rights apply only where Sentire is already market-approved. (Link)
  4. American Healthcare REIT Spends $696 Million on Eight Class A Senior Housing Communities, Launching a New LCB Operating Relationship The eight communities total 867 units across Massachusetts, Connecticut, New Jersey, Pennsylvania, Delaware and Georgia. They were carved from a ten-community sale; AHR walked the other two to a second buyer at its allocated basis — a structure owners should note when a single buyer will not take the whole book. The same week AHR closed six Kensington Senior Living communities for about $572 million, part of an eight-community, 745-unit portfolio priced near $873 million and described as well below replacement cost. Year-to-date investments now exceed $2 billion. (Link)
  5. LTC Properties Pays $200 Million for Four Minnesota SHOP Communities at a 7% Year-One Cap Rate The four assets are 453 independent living, assisted living and memory-care units with an average age of nine years. Unlevered IRR is guided to the low- to mid-teens. About $167 million of the check came from selling 13 Texas skilled-nursing centers — a rotation out of triple-net SNF into operator-aligned seniors housing, now 38% of annualized NOI. Operator is Lifespark. Published cap-rate and IRR targets are uncommon and give private owners a reference bid. (Link)
  6. Medtronic plc (NYSE: MDT) has agreed to invest up to $80 million in Israel’s Pi-Cardia Ltd., securing global distribution rights to the ShortCut device and an option to acquire the company for up to $210 million plus earn-outs. The check is staged into Rehovot; exclusive ShortCut distribution starts in 2027; the option is milestone-based. ShortCut is the first FDA-cleared leaflet-modification tool for valve-in-valve TAVR patients at risk of coronary obstruction, with successful leaflet splitting in every pivotal-trial patient. Structural Heart GM Jorie Soskin framed it as preparing for complex-anatomy TAVR demand rather than buying the company today. (Link)
  7. Cresco Labs Inc. (CSE: CL; OTCQX: CRLBF) has closed the purchase of PharmaCann Penn, LLC for $50 million in cash and a seller note, adding nine operating medical-marijuana dispensaries in Pennsylvania The deal is cash-free and debt-free against a normalized working-capital target and is described as immediately accretive to revenue, margin and cash flow. Pennsylvania is the second-largest U.S. medical cannabis market, with more than $1.1 billion of sales last year. The stores deepen an existing Mid-Atlantic retail bench rather than opening a new state. No earn-out was disclosed. (Link)
  8. Fortrea Holdings Inc. (NASD: FTRE) will buy Worldwide Clinical Trials’ Early Phase Services unit for about $45 million in cash. The package is a 200-bed GCP clinical pharmacology unit in San Antonio, a 60,000-square-foot GLP bioanalytical lab in Austin and a biospecimen store in Pflugerville. Fortrea picks up captive large- and small-molecule bioanalysis and more first-in-human beds. Worldwide keeps late-stage oncology, neuroscience, internal medicine and rare disease and will still place Phase I work through a services alliance. Close is subject to licenses and those agreements. Barclays and Mintz advised Fortrea; BroadOak and Greenberg Traurig advised Worldwide. (Link)
  9. Discovery’s Vitality Acquires Icario in a Reported R958 Million Deal, Building a Payer Platform Covering 30% of U.S. Health Plans The combined stack reaches 19 million members, including eight of the ten largest U.S. plans. The parties themselves did not disclose value; the R958 million figure is from South African press. Member engagement is now a Stars-and-risk-adjustment revenue lever rather than a wellness line item. The buyer is a non-U.S. strategic writing a check for scaled U.S. payer distribution — a class domestic sellers should not overlook. (Link)
  10. HCA Healthcare, Inc. (NYSE: HCA) has sold Dominion Hospital in Falls Church, Virginia to New York-based senior care operator Hill Valley Healthcare for $25 million. The buyer, founded in 2018, runs more than 40 facilities across six states. This is its first behavioural-health asset and part of a push into Virginia. Dominion treats children, adolescents and adults, including eating-disorder and trauma programmes. HCA keeps 430 inpatient behavioural beds and 19 outpatient programmes in the state. (Link)
  11. PACS Group, Inc. (NYSE: PACS) has signed definitive agreements to acquire the operations of 32 Florida skilled nursing facilities leased from Omega Healthcare Investors, Inc. (NYSE: OHI).  Florida is the company’s 21st state. The package adds 4,049 licensed beds concentrated in the Tampa, St. Petersburg and Orlando corridor, with close expected in the fourth quarter. Chairman and CEO Jason Murray framed the state as demographically driven growth; shares rose 3.3% premarket. (Link)
  12. H.I.G. Capital has completed the acquisition of Outcomes One, the Orlando-based clinical network services and pharmacy technology provider led by Chief Executive Jude Dieterman. The Miami firm, with $75 billion under management, bought through an affiliate; terms were undisclosed. The asset pairs network reach with recurring software: a clinical network touching roughly 85% of U.S. pharmacies, more than 10 million interventions in 2025 across 130 million covered lives, and platforms including Rx30, Computer-Rx and Outcomes Premium. Managing Director Arjun Mohan framed the thesis as elevating the pharmacy’s role in care delivery. Customers span national chains, health systems, specialty and long-term care, and independents. (Link)
  13. CVC, through its Strategic Opportunities III platform, has agreed to invest in Unitex Textile Services LLC alongside the Potack family, taking the first outside equity in the healthcare linen group’s 100-year history.  Founded in 1922 and based in Elmsford, New York, Unitex is the leading outsourced healthcare textile manager in the Northeast, serving more than 5,000 hospitals, outpatient sites and nursing homes through an automated processing network. Chairman Michael, CEO Robert and President David Potack keep a significant stake and continue to run the company. Proceeds fund operations, commercial work, digital capability, greenfield sites and bolt-ons. The underwriting is scale, route density and long-tenured accounts. (Link)
  14. Labcorp (NYSE: LH) has acquired MLM Medical Labs, expanding its central-laboratory and biomarker network across the United States, Germany and South Africa.  Labcorp says that makes it the only independent central lab with a wholly owned network on four continents. MLM operates Africa’s first fully CAP-accredited central laboratory and adds biomarker and specialty testing for multinational trials. Labcorp employs about 71,000 people, supported more than 85% of FDA new-drug approvals in 2025 and ran more than 750 million tests. No price was disclosed. (Link)
  15. Bain Capital-backed LeanTaaS has acquired Aidin, the care transition platform founded and led by Russell Graney, to extend iQueue for Inpatient Flow through discharge and placement.  LeanTaaS is already in about 200 health systems and more than 1,200 facilities. Aidin serves 200-plus hospitals across roughly 20 systems and coordinates more than two million referrals a year through 21,000-plus post-acute providers. Published results: 0.86 days off average length of stay, placement time halved, and about $1.7 million of annual savings per hospital. Bain partner Paul Moskowitz framed the return as capturing both the avoided day and the freed bed. Terms undisclosed. (Link)
  16. Stryker (NYSE: SYK) has signed a definitive agreement to acquire privately held ZuriMED, developer of the commercialized FiberLocker System for rotator-cuff augmentation.  ZuriMED is a Zurich company out of ETH Zurich, the University of Zurich and Balgrist. FiberLocker is an FDA-cleared (510(k), late 2024) single-use system: a non-degradable polyester SpeedPatch PET felt plus a dedicated instrument that mechanically felts the patch into repaired cuff tissue. Published retear rates after cuff repair run from 24% to 94%; the device is indicated to reinforce suture or anchor repair where the soft tissue is weak. The parties will operate separately until close. (Link)
  17. Quva has acquired Central Admixture Pharmacy Services’ 503B product portfolio after CAPS, a B. Braun unit, exited 503B sterile compounding.  Named SKUs include cardioplegia, total parenteral nutrition and heparin. Quva runs more than 200,000 square feet of FDA-registered 503B plants in New Jersey and Texas and 100,000 square feet of forward distribution in Texas and Arizona, and already serves more than 3,500 U.S. hospitals. Selected products start later in 2026, with the rest over the following six months. Local CAPS 503B staff are being offered roles. (Link)
  18. VION Biosciences, based in Shaker Heights, Ohio, has closed its acquisition of Prolytix. The add-on brings regulated large-molecule bioanalytical and CMC work — PK, ADA and immunogenicity, biomarkers, method validation, release and stability — plus research reagents, plasma and coagulation proteins, IVD inputs and custom collection devices. Those lines sit next to CTL immune monitoring and Ansh Labs on a Brooke PE / LongWater / Twin Bridge platform. CEO Mark Thornton framed the gap as documentation-heavy services and workflow-critical reagents. (Link)
  19. Serent Capital-backed Aria Care Partners has acquired Precision Mobile Care, the Utah mobile dental provider led by Principal John Flanders.  The Overland Park platform already delivers dental, vision, audiology and podiatry plus insurance into skilled nursing facilities and has converted a ten-year insurance relationship into ownership. Precision serves thousands of residents in more than half of Utah’s SNFs with on-site preventive and restorative dental care. This is Aria’s third acquisition of 2026, after the February Sanford dental and vision platform in Georgia and Alabama. Aria partners with more than 3,500 facilities nationally; client-facing teams and schedules stay. (Link)
  20. Incline Equity Partners-backed West Physics Consulting, LLC has acquired Radiographic Testing Services, Inc., the Albany, New York medical physics provider.  West Physics, Atlanta-based and sponsor-backed since June, is on its ninth disclosed add-on. RTS, founded in 2011, covers nuclear medicine, diagnostic radiology, radiation oncology and Certified Radiation Equipment Safety Officer work across central New York. An Albany field office lets the platform meet New York requirements centrally and reach Boston and Philadelphia. CEO Dr. Geoffrey West cited local relationships and state regulatory familiarity. (Link)

Venture Deals and Other

  1. Noteus Partners has led a $90 million equity round in Scan.com with participation from Aviva (LSE: AV.), Concord Health Partners, YZR Capital and Oxford Capital, alongside $130 million of debt facilities from VerisFi Capital and Atempo Growth. vCombined capital is $220 million after revenue doubled to a $165 million annualised run-rate. The debt is earmarked for M&A and working capital in a U.S. imaging market where 85% of scans are still booked by fax or phone. Noteus GP Nathalie Bruls cited patient experience, provider connectivity and proprietary data; Concord’s James Olsen tied it to access and cost. More than 900,000 patients have used the network globally. (Link)
  2. Morgan Health has led a Series E of more than $125 million in Thyme Care at a valuation above $2 billion, joined by Humana Inc. (NYSE: HUM), CVS Health Ventures — the corporate arm of CVS Health Corporation (NYSE: CVS) — AlleyCorp, HealthQuest Capital, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health. The syndicate pairs two national payers with community-oncology, health-system and employer-benefit capital. Reach is 10.5 million people across all 50 states and more than $7 billion of oncology spend, with validated 5–10% reductions in total cost of care. The company reports profitability and positive free cash flow. Proceeds also capitalise Thyme Companies, a new parent building independent oncology businesses aimed at biosimilar adoption and trial accrual. Morgan Health CEO Dan Mendelson cited continued conviction in payer-side value delivery. (Link)
  3. Ultrahuman has raised $70 million — $65 million of equity and $5 million of debt — at a reported $365 million valuation, with Qualcomm Ventures, Labcorp, Alpha Wave, Blume Ventures, Nexus Venture Partners and Alteria Capital. The Bengaluru company says it has sold about 800,000 rings and is running at a $140 million revenue run-rate, targeting $200 million by January 2027. It currently uses Nordic Semiconductor silicon and is adding Qualcomm chips so more algorithms run on the ring rather than the phone or cloud. Part of the money funds a deeper link between ring physiology and Labcorp blood-testing data, plus expansion in India and the UAE. (Link)
  4. BVF Partners, L.P. has led an oversubscribed $60 million Series B in Superluminal Medicines with new investors Deep Track Capital and Perceptive Advisors joining existing backers RA Capital Management, Insight Partners, NVIDIA Corporation (NASD: NVDA), Catalio Capital Management, Eli Lilly and Company (NYSE: LLY), Cooley and Gaingels. The round funds the move from discovery platform to clinic. NVIDIA is the compute check; Lilly is both investor and GPCR collaboration partner. Proceeds take a selective, biased MC4R agonist into Phase 1 by year-end 2026 for rare genetic and hypothalamic obesity. BVF’s Harsha Paladugu cited differentiated small molecules against historically intractable GPCRs; RA Capital’s Nandita Shangari pointed to syndicate calibre as validation of platform translation. (Link)
  5. Elucid has closed an oversubscribed $55 million Series D with a new unnamed publicly traded medtech strategic investor joining IAG Capital Partners and Elevage Medical Technologies, the platform created by Patient Square Capital. The company raised after FDA clearance and reimbursement, not before. Total capital is about $185 million since 2009; valuation undisclosed. The new backer is Elucid’s fourth publicly traded strategic — an unusual concentration for software-only cardiovascular diagnostics. Plaque-IQ was cleared in October 2024 and has been reimbursable under CPT 75577 at a national average of about $1,012 per scan since January 2026. BioIntegrated FFR-CT remains in 510(k). Proceeds fund commercial expansion and clinical studies. (Link)
  6. Hi Rasmus has taken a $50 million minority growth-equity investment from Updata Partners. The Nashville ABA software company was founder-controlled and previously bootstrapped. It now serves about 1,000 organizations and 19.6 million client session hours a year and ranked No. 7 on the 2026 Inc. Regionals Southeast list on 1,069% two-year growth. Braden Snyder of Updata joins the board. No change of control; management says it does not plan another raise. (Link)
  7. EIT Pharma has closed an oversubscribed $35 million Series A led by Propel Bio Partners. EIT is taking lonafarnib, an investigational first-in-class oral therapy for chronic hepatitis D in patients already infected with hepatitis B, through FDA review. The company says it is the only oral candidate in late-stage CHD development and that the NDA has been accepted. Lonafarnib is designed for oral dosing and room-temperature storage. Good Ventures and Arrowtown joined. Proceeds fund continued FDA review, manufacturing and commercial readiness if approved, plus the rest of the infectious-disease pipeline. Safety and efficacy are not established. (Link)
  8. Labcorp Venture Fund, the strategic arm of Labcorp Holdings Inc. (NYSE: LH), has led a $32 million Series B in N-Power Medicine with continued participation from the Merck Global Health Innovation Fund of Merck & Co., Inc. (NYSE: MRK), Innovatus Capital Partners and a leading US biotech investor. The Labcorp check is the second industry-leader investment in the Redwood City company after Merck GHI. The product is ProECA, which builds prospective, trial-grade external control arms from routine community cancer care and is meant to cut randomisation, sample size and timelines. The initial NSCLC programme runs across more than 40 community oncology sites and is already used by sponsors for early-phase and Phase 4 work. Colorectal and prostate platforms follow later this year. Proceeds scale the network and pharma partnerships. (Link)
  9. Chicago-based PatientIQ has closed a $30 million Series C led by Hughes & Company, with Health Enterprise Partners and August Capital. The outcomes platform now covers 870-plus healthcare organizations, 17 million patients and more than 70 million collected outcomes across 20-plus specialties and 50-plus EHR integrations, including Epic, Oracle Cerner and Athenahealth. It powers registries for AAOS, AANS and STS. Proceeds fund deeper specialty and health-system penetration, real-world evidence for device and life-science customers, and a direct-to-patient marketplace. Travis Hughes joins the board. (Link)
  10. Madrona and General Catalyst have led the close of NewDays’ seed round at $16 million, as the Seattle AI dementia care company launches in Nevada. The same pair co-led the original $7 million seed; this take-up brings the seed to $16 million total. The pitch is a staffing bottleneck: cognitive therapies work but depend on a small bench of trained clinicians. NewDays pairs monthly or twice-monthly telehealth visits with unlimited sessions with an AI companion, Sunny. Research presented at the Alzheimer’s Association International Conference in July showed patients outperforming historical decline curves by about 18 months of preserved function — on 24 patients. Nevada is the sixth state. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 24th, 2026

LECO_Weekly-Healthcare-News_8-24-2026Download

Healthcare Weekly News and Deals

  1. Francisco Partners to take Weave Communications (NYSE: WEAV) private for $650 million in an all-cash deal at $7.40 per share. The price is a 34% premium to Weave’s Monday closing price, and the company will delist after going public in 2021. The sponsor is buying a vertical platform serving independent medical, dental, optometry and veterinary practices, a customer base most software companies overlook. Weave generated $239 million of fiscal 2025 revenue, up 17%, and $65.5 million in the first quarter of fiscal 2026, also up 17%, yet its market value sits well below the $1.4 billion peak. Francisco Partners raised more than $75 billion and previously bought AdvancedMD for $1.125 billion. (Link)
  2. Universal Health Services (NYSE: UHS) has closed its $835 million debt-financed acquisition of virtual behavioral care provider Talkspace (NASD: TALK). The transaction valued Talkspace at $5.25 per share and was financed with debt. Talkspace keeps its brand and organizational structure, with CEO Jon Cohen reporting directly to UHS President and CEO Marc Miller. The target reported $229 million in revenue, $4.8 million in net income and $15.8 million in adjusted EBITDA in 2025, and runs a virtual network of more than 6,000 behavioral health professionals. Behavioral health already generated about 43% of the buyer’s $17.4 billion 2025 revenue, and UHS expects the deal to be slightly accretive to adjusted net income in the first year after closing. (Link)
  3. Thoma Bravo has to take Accelerant (NYSE: ARX) private at $20.25 per share in an all-cash deal valuing the specialty insurance risk exchange above $4 billion, with existing backer Altamont Capital Partners rolling over. The offer is a 49% premium to Accelerant’s closing price on 12 August 2026. Altamont Capital Partners, which controls around 82% of voting rights, supports the deal, and Altamont and the founders intend to keep an equity interest alongside Thoma Bravo. Thoma Bravo has committed equity, so completion does not depend on additional financing, and shareholders receive a 6% annual ticking fee if insurance regulatory approvals delay closing. Senior partner A.J. Rohde tied the thesis to MGA market growth. (Link)
  4. BioMarin (NASD: BMRN) to acquire Alesta Therapeutics for $275 million BioMarin Pharmaceutical has agreed to acquire Alesta Therapeutics to gain ALE1, a clinical-stage oral small molecule for hypophosphatasia. BioMarin will pay $275 million upfront and up to $215 million in development and regulatory milestones. Alesta will spin out all non-ALE1 assets prior to closing. ALE1 is being evaluated in a Phase 1/2a trial and has the potential to become the first oral therapy for the rare genetic bone disease. Closing is expected this quarter. (Link)
  5. Cityblock Health has signed an all-stock agreement to acquire Homeward Health and separately raised a $116 million Series E led by General Catalyst. Financial details of the all-stock acquisition were not disclosed. The $116 million Series E was led by General Catalyst and takes total capital raised past $900 million, against a $400 million 2021 round that set a roughly $5.7 billion valuation. The company says it is not focused on an exit at this time. Cityblock serves almost 200,000 members at $2.2 billion of annualized revenue, up 77% year over year, and the two businesses together will serve nearly 250,000 people. (Link)
  6. R1 to acquire Humata Health, the AI prior authorization company, to extend its Phare Operating System into payer-provider authorization workflows. Pricing was not disclosed and both parties are private. The investment case is denial prevention: prior authorization is a top-three driver of denials, and a KFF survey found one-third of insured adults call it the biggest burden in accessing care. Humata’s agentic workflows match payer policy, build AI-driven clinical bundles and manage requests to final approval, delivering up to a 96% first-pass approval rate while cutting write-offs by 30%, rescheduled appointments by 83% and staff touches by 45%. R1 folds the capability into Phare Intelligence and Payer Atlas and uses it to sell adjacent modules. (Link)
  7. Goldman Sachs Asset Management-backed Advanced Recovery Systems has acquired Promises Behavioral Health from Assured Healthcare Partners. Terms were not disclosed. Promises was previously backed by Assured Healthcare Partners, which converted its debt into equity in late 2021, after BlueMountain Capital Management bought the assets of bankrupt Elements Behavioral Health in 2018. Combined, the company operates 24 facilities in 14 states across medical detox, inpatient, residential and outpatient services. Goldman halted an auction of Advanced Recovery Systems in January, and addiction treatment dealmaking has fallen sharply, with six closings in the first half of 2026 against 19 a year earlier.(Link)
  8. General Catalyst-backed Radial has acquired TMS Health Partners, the MSO behind Mindful Health Solutions, delivering an exit for previous backer Aisling Capital. Terms were not disclosed. Radial is less than a year into its holding period with General Catalyst and has multiplied its clinical footprint with a single transaction. The combination brings Radial to 27 clinics across seven states, most of them from Mindful Health Solutions. The deal also caps a quick turnaround for Aisling Capital. Radial supports clinics with drug and device procurement, billing and RadialOS, an AI clinical decision support tools. (Link)
  9. Flexpoint sells ArtesRx to Linden Capital Partners Flexpoint Ford has completed the sale of ArtesRx, its specialty behavioral health pharmacy platform, to Linden Capital Partners. Formed in 2023, ArtesRx focuses on complex medication regimens for patients with serious mental illness, substance use disorders, and intellectual and developmental disabilities. Under Flexpoint ownership the platform expanded from three pharmacies in a single state to 16 locations across 15 states through organic growth and targeted M&A. Financial terms were not disclosed. (Link)
  10. BPOC partners with Master Medical Equipment and ReNew Biomedical BPOC has made strategic investments in Master Medical Equipment and ReNew Biomedical, sister companies that provide capital equipment distribution, rental, repair and preventative maintenance services to the pre-hospital and post-acute markets. The Jackson, Tennessee-based businesses offer new and refurbished equipment along with biomedical service across a national footprint. Founder and CEO Mark Taylor will continue to lead the companies. Financial terms were not disclosed. (Link)
  11. Truehelm and QHP Capital-backed InformedDNA has divested its Genetic Testing Utilization Management business unit to Zyter, a subsidiary of global technology company Infinite. Terms were not disclosed. InformedDNA is a portfolio company of Truehelm and QHP Capital, and the sale follows the May 2026 divestiture of its Payment Integrity business unit. The sponsors are concentrating remaining capital behind DNAimpact, InformedDNA’s precision health platform, rather than running three businesses at once. The divested unit pairs genetics-trained specialists with evidence-based review for health plans, a capability that grows more valuable as genetic test volume and complexity compound. Truehelm partner and board member Conor Green described the process as sharpening InformedDNA’s focus. (Link)
  12. U.S. Oral Surgery Management, backed by Oak Hill Capital, has partnered with Cottonwood Oral & Maxillofacial Surgery of Albuquerque in its third New Mexico transaction. Terms were not disclosed and both parties are private. USOSM is a management services organization that works exclusively with oral and maxillofacial surgeons and now spans 31 states. The specialist-only mandate is the differentiator against general dental consolidators, and single-practice tuck-ins remain the primary growth mechanism. CEO Doug Drew pointed to clinical reputation, patient care and safety as the selection criteria for the practice. USOSM provides operational, financial and administrative support to surgeons alongside wealth creation. (Link)
  13. Integrated Dermatology has entered the Kentucky market through a partnership with Knuckles Dermatology, which now operates as Integrated Dermatology of Kentucky. Terms were not disclosed and both parties are private. The partnership took effect August 18, 2026 and covers patients in Corbin, Richmond and surrounding southeastern Kentucky communities. Dr. Knuckles continues to practice, and two board-certified family nurse practitioners, Lauren Hayes and Jordan Patterson, join to expand provider capacity. Established in 2004, Integrated Dermatology operates in nearly 30 states and offers dermatologists profit-sharing and full clinical autonomy while handling operational and administrative work centrally.(Link)
  14. Concentra (NYSE: CON) has completed the acquisition of four Minnesota Occupational Health medical centers in the Twin Cities, taking its statewide network to 10 sites. Terms were not disclosed. The four acquired centers sit in Coon Rapids, Eagan, St. Paul Midway and Shakopee, and began operating as Concentra on August 17. Concentra has served Minnesota since 2018 and will now run 10 medical centers across the state. The buyer also plans significant investment in the St. Paul Midway center to make it a regional flagship. The economics rest on density and employer cross-selling across injury care, physical therapy, drug testing and DOT exams. (Link)
  15. Momentum Health Partners has expanded its investment in Desert Pain Specialists, the Rancho Mirage, California interventional pain management practice it first backed in 2023. The amount was not disclosed. The Phoenix-based platform deployed additional capital into Desert Pain Specialists following the acquisition and integration of Dr. Roland Reinhart’s pain management practice. The new capital funds physician recruitment, service line expansion and operational growth across California’s Coachella Valley, where the practice has posted growth in new patient volumes since integrating. Partner Ryan Harper framed the follow-on as confidence in the team. Momentum invests across autism therapy, developmental therapies, behavioral health and specialty ambulatory care. (Link)
  16. SEVA has made a growth equity investment in healthcare price transparency company Serif Health, the first outside institutional capital the San Francisco business since 2020 launch. Terms were not disclosed. The round is Serif Health’s first outside institutional capital since it launched in 2020, and SEVA founder and managing partner Shalin Mehta joins the board. Serif cleans, validates and standardises pricing data from hundreds of payers and thousands of hospitals through its Signal platform, used by more than 250 organisations to benchmark rates, evaluate networks and track market dynamics. Proceeds accelerate sales and expand a pipeline of product features and data APIs, following the 2026 launch of Signal Ask, a plain-language query tool. (Link)
  17. Providence Equity Partners to acquire a majority stake in CheckedUp, with Varsity Healthcare Partners joining as strategic minority. Terms were not disclosed. Providence is acquiring alongside the co-founders, who continue to lead the company, and Varsity Healthcare Partners as a healthcare services-focused minority investor. CheckedUp reaches >17,000 specialty healthcare providers and 15 million patients through waiting-room televisions and interactive exam-room wallboards, and works with most of the top 40 pharmaceutical manufacturers. Providence is underwriting this as a digital out-of-home media asset, consistent with prior positions in OUTFRONT Media, DoubleVerify and Smartly.io. (Link)
  18. Cypress Ridge Capital-backed Cresso Health has partnered with Slate Financial, the Southwest Medicare and health insurance distributor. Terms were not disclosed. Cresso Health is backed by New York-based healthcare investor Cypress Ridge Capital. The logic is distribution roll-up economics. Slate gains access to Cresso’s carrier relationships, distribution infrastructure, proprietary marketing and lead-generation tools and compliance toolkit, while Cresso extends its field presence. CEO Frank Pistone described the goal as an omni-channel, multi-product platform serving the senior market. Cypress Ridge invests exclusively in healthcare with a thematic, growth-oriented approach. (Link)
  19. Rockmont Partners has exited RepScrubs, the automated scrubs dispensing platform, with THL named as acquirer in Healthcare DealHub’s headline. Terms were not disclosed. Healthcare DealHub titles the transaction as THL acquiring RepScrubs from Rockmont Partners, while the deal note itself describes the buyer as undisclosed. Rockmont led a secondary purchase in the business in 2024, making this a short hold. RepScrubs runs an automated scrubs dispensing platform that manages vendor credentialing and enforces policy compliance for perioperative vendors at hospitals and surgery centers. The asset sits in digital and health technology, which has recorded 289 tracked deals year to date. (Link)
  20. Berks Community Health Center to merge with Lancaster-based Union Community Care, a distress-driven nonprofit combination pending regulatory approval. No purchase price applies. Board vice chair Missy Orlando named two financial triggers, starting with a sharp drop in federal Medicaid funding from January that could cost roughly 100,000 Berks County residents their benefits. The center has also struggled to collect patient payments and lost several providers over the past year. Union Community Care operates 25 locations across Lancaster, Lebanon and Chester counties, covering family medicine, urgent care, dental, school-based care, behavioral health and pharmacy. (Link)
  21. Mitsui Chemicals (Tokyo: 4183) has completed its acquisition of Utah-based dental products maker Ultradent Products, making it a wholly owned subsidiary alongside existing dental unit Kulzer. The deal closed on August 14, ahead of the September 2026 schedule, after competition and investment approvals came through early. Mitsui is making oral care the third earnings pillar of its Life & Healthcare Solutions segment and targeting the number two position in global dental materials. The company expects more than $40 million in annual synergy by fiscal 2030. Integration moves the oral care global headquarters to the United States, with Ultradent CEO Dirk Jeffs also taking over as Kulzer CEO while Kulzer’s Chris Holden becomes Chief Strategy and Integration Officer of MC Dental Holdings America.(Link)
  22. Osage Venture Partners-backed Curavit Clinical Research has acquired the CRO assets of Lindus Health, which is shifting to its own therapeutic pipeline as Lindus Therapeutics. Terms were not disclosed. The transaction follows Lindus shifting focus to developing its own pipeline of therapeutic assets. What Curavit bought is European delivery capability, not scale for its own sake: the combined business can now run decentralized, hybrid and traditional trials across North America and Europe under one operational partner. Nate Lentz, managing partner at Osage Venture Partners and a Curavit board member, tied the thesis to sponsors needing more flexible, technology-enabled approaches to generating clinical evidence. CEO Joel Morse positioned the platform against both regional niche CROs and legacy providers. (Link)

Venture Deals and Other

  1. 8VC and Town Hall Ventures have led a $53 million Series D in Hopscotch Primary Care. 8VC and Town Hall Ventures led the round, with existing investors aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures participating and new investors including the Autism Impact Fund, Kleiner Perkins chairman John Doerr, Heritage Provider Network founder Dr. Richard Merkin and the Leon Levine Foundation. Founded in 2021, Hopscotch serves more than 15,000 patients across the rural Southeast, concentrated in western North Carolina. Investors have hard numbers to point at: a Net Promoter Score of 89, patient retention above 90%, medical loss ratio improvement of more than 25 percentage points over two years and profitable operations in western North Carolina. (Link)
  2. Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital have funded Network Bio’s $50 million launch alongside an NVIDIA partnership. Network Bio, a Palo Alto company building AI models trained on human biological data, launched on August 19 with $50 million from investors including Section 32, Thiel Bio, Founders Fund, Breyer Capital, Blue Venture Fund and JSL Health Capital. The money funds a research network with Mass General Brigham, the University of Pennsylvania and the University of Colorado Anschutz, supplying tissue and blood samples paired with longitudinal clinical outcomes across immunology, metabolic, cardiovascular and autoimmune disease. Investors are paying for exclusive data access rather than a clinical asset. The launch came with an NVIDIA partnership to scale the models. (Link)
  3. InnovaHealth Partners led Channel Medsystems’ Series C to $30 million, backing the commercial expansion of the Cerene endometrial cryotherapy platform. The Berkeley medical technology company has reached $30 million in an ongoing Series C led by InnovaHealth Partners. InnovaHealth has backed Channel Medsystems since 2021. Proceeds fund commercial organization expansion, physician and patient awareness, professional education and training, clinical evidence generation and market development infrastructure. The raise follows a commercial relaunch of the platform. Founder and Managing Partner Mortimer Berkowitz III pointed to unmet need in women’s health backed by clinical evidence and an experienced leadership team. (Link)
  4. MaxQ Medical raises $31.5 million Series A backed by Olympus MaxQ Medical has closed a $31.5 million Series A led by Atlantic Blue Ventures, S3 Ventures and Olympus Innovation Ventures, with participation from Hillside Capital. The financing advances the company’s transurethral imaging-and-therapy platform for prostate disease, the first spinout from Orchard Ultrasound Innovation. The system combines real-time imaging with tissue-selective therapy in a single outpatient procedure, initially targeting BPH with planned expansion into focal therapy for prostate cancer. Proceeds support clinical program advancement and team expansion. (Link)
  5. Leal Therapeutics announces $30 million Series A extension Leal Therapeutics has completed a $30 million second close of its Series A, adding Eli Lilly as a new investor alongside existing backers OrbiMed, Newpath Partners, Euclidean Capital, SV Health Investors’ Dementia Discovery Fund and others. Proceeds will advance LTX-001, a first-in-class brain-penetrant oral GLS1 inhibitor, through initial readout of its newly initiated Phase 1b/2a trial in schizophrenia, and progress LTX-002 through additional dosing cohorts in an ongoing Phase 1/2 ALS study. (Link)
  6. Werewolf Therapeutics and Ambros Therapeutics announce merger and concurrent $150 million private placement Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics have entered an all-stock merger agreement accompanied by an oversubscribed $150 million private placement co-led by RA Capital and Janus Henderson. The combined company, to operate as Ambros Therapeutics and trade as AMBX, will advance neridronate in the pivotal CRPS-RISE Phase 3 trial for Complex Regional Pain Syndrome Type 1. Capital is expected to fund operations through Phase 3 topline results, planned NDA submission and into the first half of 2029. (Link)
  7. Gossamer Bio announces up to $250 million structured private placement Gossamer Bio has arranged a structured private placement of up to $250 million, including $150 million of committed capital, to fund development of seralutinib through potential FDA approval. The financing extends runway for late-stage clinical and regulatory activities surrounding the company’s lead pulmonary arterial hypertension program. (Link)
  8. Biotechnology investor Bob Nelsen has led a $20 million round in Astromech, joined by Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, lifting the Colossal Biosciences spinout to a $3.8 billion valuation. The round was led by Bob Nelsen with participation from Peak 6, NeoGenesis Capital, Builders VC and CAZ Investments, bringing total capital raised to $60 million. The valuation is unusual relative to check size, and what investors are buying is founder pedigree and a data position rather than near-term revenue. Astromech was co-founded by Ben Lamm and geneticist George Church, spun out of Colossal Biosciences, and uses 3.8 billion years of evolutionary history as a primary training signal. Longevity is the proving ground, with 46 longevity-associated genes mapped so far. (Link)

CLICK HERE to sign up
for all news and updates